Abemaciclib adjuvant (HR+/HER2- early high-risk breast cancer)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-ABEMACICLIB |
|---|
| ID | REG-ABEMACICLIB-ADJUVANT |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-MONARCHE-JOHNSTON-2023 SRC-NCCN-BREAST-2025 |
Notes
STUB — pending Co-Lead sign-off. monarchE: 2-year fixed-duration adjuvant CDK4/6i for high-risk HR+/HER2- early BC. Key AEs: diarrhea (most common, usually G1-2, manageable with loperamide), neutropenia (CBC q2w x 2 months, then monthly), hepatotoxicity (LFT monitoring), VTE. Strong CYP3A4 inhibitors increase abemaciclib exposure significantly — dose reduction required. NO benefit beyond 2 years per current data; fixed-duration design. Concurrent endocrine therapy (AI or tamoxifen) is required throughout.
Used By
Indication
IND-BREAST-HR-POS-EARLY-ADJ-CDK46I- IND-BREAST-HR-POS-EARLY-ADJ-CDK46I